Document 3010
 DOCN  M94A3010
 TI    An alternative choice to stage (and treat) the epidemic Kaposi's sarcoma
       (EKS).
 DT    9412
 AU    Moresco L; Scala M; Meszaros P; Badellino F; Clinical and Exp. Onc.
       Inst., University of Genoa, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):174 (abstract no. PB0121). Unique
       Identifier : AIDSLINE ICA10/94369565
 AB    In order to classify the EKS according to the TNM programs, and to
       propose an alternative treatment for EKS patients (pts.), from June 1991
       to Sept. 1993, two study-groups of pts. were investigated. In the first
       group 314 pts. were staged according to the--Tumor, Immune system,
       Sistemic illness (TIS) classification (c.), proposed by Krown
       (ACGT-USA). TIS c., slightly modified according to some our oncological
       criteria, takes into account three major parameters: T1, T2, (anatomical
       and morphological features of the lesions [1.]); IO, I1, (Immune system,
       CD4+ count); SO, S1, S2, (systemic illness). Our data showed that no
       significant difference on 5 years survival was observed in T1-T2
       subgroups. A slight, although non significant, difference were observed
       comparing S0, S1, S2 subgroups. Conversely, significant survival
       differences were observed in I1-I1 subgroups. Our results suggest that
       immunological status appears the major responsible of clinical outcome
       in EKS pts. In the second study-group, cryosurgery in association with
       chemotherapy, was carried out in 3 pts. with 1. spreading to: mouth (1
       case), eye (1 case), mouth, nose, penis (1 case) and affected from
       bleeding, burning, or dysphagia. In all 3 pts, a complete recovery of
       the treated 1. were observed with a persistent clinical improvement.
 DE    Acquired Immunodeficiency Syndrome/MORTALITY/*PATHOLOGY/THERAPY
       Chemotherapy, Adjuvant  Combined Modality Therapy  Cryosurgery  *Disease
       Outbreaks  Follow-Up Studies  Human  Neoplasm Staging  Sarcoma,
       Kaposi's/MORTALITY/*PATHOLOGY/THERAPY  Skin
       Neoplasms/MORTALITY/*PATHOLOGY/THERAPY  Survival Rate  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).